- Home
- PWM vs LTRN Comparison
PWM vs LTRN Comparison
Compare PWM & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PWM
- LTRN
- Stock Information
- Founded
- PWM 2018
- LTRN 2013
- Country
- PWM Hong Kong
- LTRN United States
- Employees
- PWM N/A
- LTRN N/A
- Industry
- PWM
- LTRN Biotechnology: Pharmaceutical Preparations
- Sector
- PWM
- LTRN Health Care
- Exchange
- PWM Nasdaq
- LTRN Nasdaq
- Market Cap
- PWM 12.4M
- LTRN 36.0M
- IPO Year
- PWM 2023
- LTRN 2020
- Fundamental
- Price
- PWM $0.43
- LTRN $3.76
- Analyst Decision
- PWM
- LTRN Strong Buy
- Analyst Count
- PWM 0
- LTRN 1
- Target Price
- PWM N/A
- LTRN $25.00
- AVG Volume (30 Days)
- PWM 6.3M
- LTRN 285.1K
- Earning Date
- PWM 07-22-2025
- LTRN 08-07-2025
- Dividend Yield
- PWM N/A
- LTRN N/A
- EPS Growth
- PWM N/A
- LTRN N/A
- EPS
- PWM N/A
- LTRN N/A
- Revenue
- PWM $639,912.00
- LTRN N/A
- Revenue This Year
- PWM N/A
- LTRN N/A
- Revenue Next Year
- PWM N/A
- LTRN N/A
- P/E Ratio
- PWM N/A
- LTRN N/A
- Revenue Growth
- PWM 83.60
- LTRN N/A
- 52 Week Low
- PWM $0.31
- LTRN $2.55
- 52 Week High
- PWM $2.70
- LTRN $6.12
- Technical
- Relative Strength Index (RSI)
- PWM 54.08
- LTRN 60.45
- Support Level
- PWM $0.39
- LTRN $3.15
- Resistance Level
- PWM $0.44
- LTRN $3.75
- Average True Range (ATR)
- PWM 0.06
- LTRN 0.34
- MACD
- PWM 0.00
- LTRN 0.08
- Stochastic Oscillator
- PWM 20.83
- LTRN 50.07
About PWM Prestige Wealth Inc.
Prestige Wealth Inc is engaged in providing private wealth management services and asset management to high-net-worth and ultra-high-net-worth individuals and enterprises through its subsidiaries.
About LTRN Lantern Pharma Inc.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.